Assessment of menstrual function during the intervention Menstrua

Assessment of menstrual function during the intervention Menstrual function was monitored daily during the intervention C646 purchase by assessing urinary excretion of E1G, PdG, and LH metabolites and the presence of menses as self-reported on monthly calendars. The methods used for the assessment and categorization of menstrual cycles are detailed and have previously been published [2]. Recovery of menstrual function categories To describe

the recovery of menstrual function, we classified recovery using several definitions of recovery that ranged in hormonal and clinical relevance. Recovery Category 1 was described simply as “recovery of menses.” The successful recovery of menses after the baseline period was defined as the first occurrence of menstrual bleeding during the intervention. For further analysis of the recovery of menstrual function, Recovery Category 2 was described as resumption of menses preceded by ovulation based on increases in urinary E1G (above 35 ng/ml), PdG (above 2.5 μg/ml), and mid-cycle LH (above 25 mIU/ml) concentrations [2, 14]. Recovery Category

3 was described as resumption of menses followed by at least 2 menstrual cycles of less than 36 days each. Anthropometrics Total body weight was measured by a digital scale during each week of the baseline period and every two weeks during Thiazovivin price the intervention. Height was measured during the screening period, and BMI was calculated as a ratio of weight to height (kg/m2). Baseline values for body weight and BMI were reported as the average of all baseline and screening measurements. Eating behavior assessment Participants completed the Three Factor Eating Questionnaire (TFEQ) and Eating Disorder Inventory-2 (EDI-2) at screening and at months 2, 3, 6, 9, and 13 (post-study) to assess eating behavior. The TFEQ

is a 51-item questionnaire with three subscales – cognitive AZD1152 dietary restraint (CDR), disinhibition, and hunger. Cognitive dietary restraint Urocanase was evaluated according to the following ranges established by Stunkard and Messick [15]: 0–10 indicated low CDR, 11–13 indicated high CDR, and 14–21 indicated the clinical range. The EDI-2 is a 91-item questionnaire with 8 subscales and 3 provisional subscales, as previously reported [16]. Scores on the first 8 subscales were compared to published means and 95% confidence intervals of eating disorder patients and non-patient college females to assess for symptoms of disordered eating and associated psychological features [17]. Body composition and bone mineral density DXA scans of the total body, lumbar spine, and dual femur were performed to assess body composition and BMD. Body composition was measured at screening and baseline and during months 1, 2, 3, 6, 9, and 13 (post-study). BMD was assessed at all three sites at screening, month 6, and month 13 (post-study).

Comments are closed.